English - Germany Priority Conditions Packet

Price: $19

An education-only research summary covering the ten main reasons German physicians gave when prescribing cannabis medicines at statutory health insurance expense (BfArM accompanying survey, 2017–2022), grouped into five sections:

- Chronic pain

- Cancer symptoms, nausea and vomiting, anorexia and wasting

- Spasticity and multiple sclerosis, migraine, restless legs syndrome

- Depression and ADHD

- Inflammatory bowel disease

What's inside:

- What published research does and does not show for each condition, with plain evidence-strength labels

- Clinician questions to weigh for every section

- Cautions that apply to all ten: psychosis, cannabis use disorder, hyperemesis, driving, pregnancy and medicine lists

- Why these ten in Germany (BfArM accompanying survey) and what German studies show, including German pain-clinic and IBD patient data

- German legal context: the 2017 "cannabis as medicine" law, the 2024 Medical Cannabis Act (MedCanG), statutory insurance approval under § 31(6) SGB V, the 2026 end of insurance coverage for flowers, and the pending bill

- Patient handoff sheets: plain-language one-card summaries a clinician may copy for patients

- 72 numbered sources; every PubMed citation checked by PMID in October 2026

14-page PDF. English edition (the governing version). A German edition is also available.

Education only. No doses, no product recommendations, no drug-interaction verdicts. Not medical or legal advice.

By Annie Romelfanger, Romelfanger Cannabis Education. romelfangercannabis.com